CAB-ADC

CAB-ADC (Conditionally Active Biologic Antibody-Drug Conjugate) is a therapeutic platform developed by BioAtla that utilizes protein engineering to create antibodies that are selectively active in the acidic microenvironment of diseased tissues (such as tumors or inflamed sites) while remaining inactive in the physiological pH of normal tissues. This pH-dependent activation is designed to expand the therapeutic window by reducing systemic toxicity and off-target effects. In recent research presented at AACR 2025, BioAtla has applied this technology to target senescent cells, specifically those exhibiting the senescence-associated secretory phenotype (SASP). These senolytic CAB-ADCs utilize duocarmycin-based payloads to selectively eliminate senescent cells in various fibrotic and inflammatory conditions, including non-alcoholic steatohepatitis (NASH) and organ-specific fibrosis (kidney, lung, heart, and liver), thereby potentially treating age-related and chronic diseases.

Other names

Conditionally Active Biologic Antibody-Drug Conjugate